Kalpit Patel
Stock Analyst at B. Riley Securities
(3.29)
# 965
Out of 4,670 analysts
50
Total ratings
42.11%
Success rate
6.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBPH Longboard Pharmaceuticals | Downgrades: Neutral | $45 → $60 | $59.80 | +0.33% | 4 | Oct 14, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $17.47 | +128.96% | 2 | Sep 20, 2024 | |
| BCYC Bicycle Therapeutics | Downgrades: Neutral | $33 → $28 | $20.54 | +36.32% | 5 | Aug 7, 2024 | |
| VSTM Verastem | Maintains: Buy | $21 → $7 | $4.00 | +75.00% | 3 | Jul 24, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $31 → $36 | $44.98 | -19.96% | 2 | Jul 9, 2024 | |
| OVID Ovid Therapeutics | Maintains: Buy | $9 → $3 | $1.05 | +185.71% | 2 | Jun 18, 2024 | |
| PDSB PDS Biotechnology | Maintains: Buy | $11 → $9 | $2.09 | +330.62% | 4 | Jun 12, 2024 | |
| VRDN Viridian Therapeutics | Downgrades: Neutral | $25 → $20 | $20.20 | -0.99% | 3 | May 9, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $13 | $26.04 | -52.00% | 3 | Mar 6, 2024 | |
| XFOR X4 Pharmaceuticals | Downgrades: Neutral | $3 → $1 | $0.34 | +195.86% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $5.37 | +11.73% | 5 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $16.09 | +123.74% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.07 | +22.85% | 2 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $3 | $0.32 | +844.58% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.21 | +714.48% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.59 | +214.47% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $0.25 | +2,280.95% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $10 | $0.68 | +1,370.59% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $16.00 | +368.75% | 2 | Sep 3, 2021 |
Longboard Pharmaceuticals
Oct 14, 2024
Downgrades: Neutral
Price Target: $45 → $60
Current: $59.80
Upside: +0.33%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $17.47
Upside: +128.96%
Bicycle Therapeutics
Aug 7, 2024
Downgrades: Neutral
Price Target: $33 → $28
Current: $20.54
Upside: +36.32%
Verastem
Jul 24, 2024
Maintains: Buy
Price Target: $21 → $7
Current: $4.00
Upside: +75.00%
Kymera Therapeutics
Jul 9, 2024
Maintains: Neutral
Price Target: $31 → $36
Current: $44.98
Upside: -19.96%
Ovid Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.05
Upside: +185.71%
PDS Biotechnology
Jun 12, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $2.09
Upside: +330.62%
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $20.20
Upside: -0.99%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $13
Current: $26.04
Upside: -52.00%
X4 Pharmaceuticals
Dec 12, 2023
Downgrades: Neutral
Price Target: $3 → $1
Current: $0.34
Upside: +195.86%
Sep 7, 2023
Reiterates: Buy
Price Target: $6
Current: $5.37
Upside: +11.73%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $16.09
Upside: +123.74%
Mar 20, 2023
Reiterates: Buy
Price Target: $5
Current: $4.07
Upside: +22.85%
Nov 11, 2022
Downgrades: Neutral
Price Target: $9 → $3
Current: $0.32
Upside: +844.58%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.21
Upside: +714.48%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.59
Upside: +214.47%
Jun 7, 2022
Maintains: Buy
Price Target: $12 → $6
Current: $0.25
Upside: +2,280.95%
Jan 24, 2022
Maintains: Buy
Price Target: $24 → $10
Current: $0.68
Upside: +1,370.59%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $16.00
Upside: +368.75%